Skip to main content
SpringerLink
Log in

Anticytokine Strategies for the Treatment of Septic Shock: Relevance of Animal Models

  • Chapter
Pathology of Septic Shock

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 216))

Abstract

For many years septic shock has been described as a complication of gram-negative bacteremia, and initial efforts at devising therapeutic approaches focused on developing antibodies directed against endotoxin (LPS), the major toxic component of gram-negative bacteria. Because recent advances in immunology have greatly contributed to our understanding of the pathophysiology of septic shock and acute inflammatory response initiated not only by LPS but also by other microbial products, many novel approaches for the treatment of septic shock have been developed in addition to anti-LPS antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abraham E, Wunderick R, Sliverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273: 934–941.

    Article  PubMed  CAS  Google Scholar 

  • Agosti JM, Fisher CJ, Opal SM, Lowry SF, Balk RA, Sadoff JC, the STNFR Sepsis Study Group (1994) Treatment of patients with sepsis syndrome with soluble TNF receptors (sTNFR) (Abstr). 34th Interscience Conference on Antimicrobial and Chemotherapy, p 65.

    Google Scholar 

  • Aiura K, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1993) lnterleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun 61: 3342–3350.

    PubMed  CAS  Google Scholar 

  • Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA (1991) A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173: 1029–1032.

    Article  PubMed  CAS  Google Scholar 

  • Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA Jr, Smith DH (1991) Protection against endotoxin shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88: 10535–19539.

    Article  PubMed  CAS  Google Scholar 

  • Bagby GJ, Plessala KJ, Wilson LA, Thompson KJ, Nelson S (1991) Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 163: 83–88.

    Article  PubMed  CAS  Google Scholar 

  • Beutler B, Milsark IW, Cerami A (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–871.

    Article  PubMed  CAS  Google Scholar 

  • Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, the Swiss-Dutch J5 Study Group (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, alpha-interferon and gamma-interferon in the serum of patients with septic shock. J Infect Dis 161: 982–987.

    Article  PubMed  CAS  Google Scholar 

  • Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975–978.

    Article  PubMed  CAS  Google Scholar 

  • Echtenacher B, Falk W, Männel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145: 3762–3766.

    PubMed  CAS  Google Scholar 

  • Emerson TE, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA (1992) Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 38: 75–84.

    PubMed  CAS  Google Scholar 

  • Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG (1992) Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148: 2724–2730.

    PubMed  CAS  Google Scholar 

  • Evans GF, Synder YM, Butler LD, Zuckerman SH (1989) Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models, Circ Shock 29: 279–290.

    PubMed  CAS  Google Scholar 

  • Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J (1994) Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180: 2173–2179.

    Article  PubMed  CAS  Google Scholar 

  • Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA (1991) Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120: 574–588.

    Google Scholar 

  • Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551–1557.

    Article  PubMed  CAS  Google Scholar 

  • Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RMH, Panacek EA, Vincent JL, Foulke GE, Warren EL, Gartrard C, Park G, Bodmer MW, Cohen J, Van der Linden C, Cross AS, Sadoff JC, the CB006 Sepsis Syndrome Study Group (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318327.

    Google Scholar 

  • Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, for the Phase III rhlL-1ra Syndrome Study Group (1994a) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836–1843.

    Article  PubMed  Google Scholar 

  • Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA, the 11-ra Sepsis Syndrome Study Group (1994b) Initial evaluation of human recombinant interleukin-1 receptor anatagonist in the treatment od sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12–21.

    PubMed  Google Scholar 

  • Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor FB, Murray CK, Peer GT, Emerson TE, Passey RB, Kuo GC (1990) Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 30: 279–292.

    PubMed  CAS  Google Scholar 

  • Hinshaw LB, Emerson TE Jr, Taylor FB, Chang ACK, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanke SD, Murray CK, Xu R, Passey RB, Fournel MA (1992) Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma 33: 668–573.

    Article  Google Scholar 

  • Jesmok G, Lindsey C, Duerr M, Fournel M, Emerson T (1992) Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Am J Pathol 141: 1197–1207.

    PubMed  CAS  Google Scholar 

  • Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A (1994) Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J Infect Dis 170: 1323–1326.

    Article  PubMed  CAS  Google Scholar 

  • Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau GE, Piguet PF, Pointaire P, Vassalli P, Loetscher H (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21: 2883–2886.

    Article  PubMed  CAS  Google Scholar 

  • Loetscher H, Angehrn P, Schlaeger EJ, Gentz R, Lesslauer W (1993) Efficacy of a chimeric TNFR-IgG fusion protein to inhibit TNF activity in animal models of septic shock. In: Levin J, Alving CR,.

    Google Scholar 

  • Munford RS, Stütz PL (eds) Bacterial endotoxin: recognition and effector mechanisms. Elsevier, Amsterdam, pp 455–462.

    Google Scholar 

  • Mancilla J, Garcia P, Dinarello CA (1993) The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 61: 926–932.

    PubMed  CAS  Google Scholar 

  • Martin RA, Silva AT, Cohen J (1993) Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes. FEMS Microbiol Lett 110: 175–178.

    PubMed  CAS  Google Scholar 

  • Mathison JC, Wolfson E, Ulevitch RJ (1988) Participation of tumor necrosis factor in the mediation of bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81: 1925–1937.

    Article  PubMed  CAS  Google Scholar 

  • Mohler KM, Torrance DS, Smith CA, Goodwin RG, Sremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548–1561.

    PubMed  CAS  Google Scholar 

  • Nassif X, Mathison JC, Wolfson E, Koziol JA, Ulevitch RJ, So M (1992) Tumour necrosis factor alpha antibody protects against lethal meningococcaemia. Mol Microbiol 6: 591–597.

    Article  PubMed  CAS  Google Scholar 

  • Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550–552.

    Article  PubMed  CAS  Google Scholar 

  • Opal SM, Cross AS, Sadoff JC, Collins HH, Kelly NM, Victor GH, Palardy GE, Bodmer MW (1991) Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 88: 885–890.

    Article  PubMed  CAS  Google Scholar 

  • Schalg G, Redl H, Davies J, Haller I (1994) Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 2: 10–18.

    Article  Google Scholar 

  • Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-a in experimental gram-negative shock. J Infect Dis 162: 421–427.

    Article  PubMed  CAS  Google Scholar 

  • Teti G, Manucuso G, Tomasello F (1993) Cytokine appearance and effects of anti-tum r necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun 61: 227–235.

    PubMed  CAS  Google Scholar 

  • Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664.

    Article  PubMed  CAS  Google Scholar 

  • Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1991) A specific receptor antagonist for interleukin 1 prevents Escherichi coli-induced shock in rabbits. FASEB J 5: 338–343.

    PubMed  CAS  Google Scholar 

  • Zanetti, G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Glauser MP, Baumgartner JD (1992) Cytokine production after intravenous of peritoneal Gram negative bacterial challenge in mice. Comparative protective efficacy of antibodies to TN and to LPS. J Immunol 148: 1890–1897.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Internal Medicine, 1040, Lausanne, Switzerland

    D. Heumann & M. P. Glauser

Authors
  1. D. Heumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. P. Glauser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Forschungszentrum Borstel, Zentrum für Medizin und Biowissenschaften, Parkallee 22, D-23845, Borstel, Germany

    E. T. Rietschel

  2. Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Trogerstr. 9, D-81675, München, Germany

    Hermann Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heumann, D., Glauser, M.P. (1996). Anticytokine Strategies for the Treatment of Septic Shock: Relevance of Animal Models. In: Rietschel, E.T., Wagner, H. (eds) Pathology of Septic Shock. Current Topics in Microbiology and Immunology, vol 216. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80186-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80186-0_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80188-4

  • Online ISBN: 978-3-642-80186-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation